Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemotherapy in Advanced HER2-Negative Breast Cancer
NCT07540533Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in breast cancer, sponsored by Henan Cancer Hospital. Started Jan 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07540533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540533.